The ALS landscape. In one view.

These panels summarize the Atlas’s current datasets. Counts describe the records covered, not the whole of ALS research. Source collections update on different schedules.

The Climb counts treatments once at their highest active phase; an approved treatment is shown in the approved column. Explorer includes trials linked to a named treatment; a multinational trial appears in each participating country. Regulator records can include multiple products for the same medicine. Literature papers and AI-read abstracts are overlapping collections and should not be added together.

A later trial phase does not establish benefit. AI-extracted claims and research leads have not been expert-reviewed; they are starting points for investigation. An approval is specific to its region and indication.